Clinical Data AZ claims another win for Imfinzi in frontline liver cancer PharmaphorumAstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.Clinical DataOncologyRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. Clinical DataOncologyRead full story Post navigation Previous: ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesityNext: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
